Lansoprazole。一个更新的药理性质和acid-related管理障碍的临床疗效。

文章的细节

引用

复制到剪贴板

Langtry高清,王尔德MI

Lansoprazole。一个更新的药理性质和acid-related管理障碍的临床疗效。

药。1997年9月,54 (3):473 - 500。

PubMed ID

9279507 (在PubMed

]

文摘

Lansoprazole是减少胃酸的分泌的质子泵抑制剂。它已被证明有效的根除幽门螺杆菌方案相结合,单一疗法治愈和缓解症状的胃或十二指肠溃疡和gastro-oesophageal反胃。初始治疗后,它可能被用来防止食管侵蚀或消化性溃疡复发的病人幽门螺杆菌不是溃疡的主要原因和减少基酸输出卓——艾氏综合症患者。常规剂量是15到60毫克/天,尽管<或= 180毫克/天的剂量已用于患者hypersecretory状态。在十二指肠或胃溃疡患者,用兰索拉唑短期单一疗法是类似于奥美拉唑和优于组胺H2受体拮抗剂在实现愈合率> 90%。Lansoprazole是一样有效的根除幽门螺杆菌方案的一个组成部分,奥美拉唑,tripotassium dicitrato铋(胶体铋subcitrate)或雷尼替丁。Lansoprazole优于雷尼替丁在症状缓解和治愈gastro-oesophageal返流性疾病,往往比奥美拉唑更快缓解症状,尽管最初的治疗是相似的。用兰索拉唑作为维持治疗,类似于奥美拉唑和优于雷尼替丁在缓解症状,防止复发。Lansoprazole也优于雷尼替丁治疗和缓解症状的食管的侵蚀与巴雷特食管;治疗是维持平均2.9年> = 70%的病人。 Lansoprazole was also superior to ranitidine in prophylaxis of redilatation of oesophageal strictures. After > or = 4 years of use in patients with Zollinger-Ellison syndrome, lansoprazole 60 to 180 mg/day effectively controlled basal acid output. Dosages may be reduced in some patients once healing and symptom relief has been achieved. Preliminary studies of lansoprazole in patients at risk of aspiration pneumonia or stress ulcers show promise. Although studies show lansoprazole is potentially effective in treating gastrointestinal bleeding, future studies should assess patients' H. pylori status. Lansoprazole has been well tolerated in clinical trials, with headache, diarrhoea, dizziness and nausea appearing to be the most common adverse effects. Tolerability of lansoprazole does not deteriorate with age and the drug is well tolerated in long term use (< or = 4 years) in patients with Zollinger-Ellison syndrome or reflux disease. Thus, lansoprazole is an important alternative to omeprazole and H2 receptor antagonists in acid-related disorders. In addition to its efficacy in healing or maintenance treatment, it may provide more effective symptom relief than other comparator agents.

beplay体育安全吗DrugBank数据引用了这篇文章

药物靶点

药物	目标	类	生物	药理作用	行动
Lansoprazole	Potassium-transporting atp酶α链1	蛋白质	人类	是的	抑制剂	细节